News

EyePoint Pharmaceuticals Set to Highlight Innovations at Conferences

EyePoint Pharmaceuticals Set to Highlight Innovations at Conferences

EyePoint Pharmaceuticals Participates in Key Conferences

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), known for its commitment to developing groundbreaking therapeutics, recently announced its participation in various significant investor conferences. The management team is eager to share insights about their innovative work, especially in the realm of retinal diseases, during these crucial events.

Upcoming Conference Schedule

EyePoint's management will be taking part in the following conferences, showcasing their latest advancements and discussions around their innovative treatments:

Citi's BioPharma Conference

Forum: Fireside Chat
Date: September 2, 2025
Time: 2:30 p.m. ET

Cantor Global Healthcare Conference

Forum: Fireside Chat
Date: September 3, 2025
Time: 2:45 p.m. ET

Morgan Stanley Annual Healthcare Conference

Forum: 1x1 Investor Meetings
Date: September 9, 2025

Webcast Availability

For those interested in following the presentations, a live webcast will be available along with an archived replay. This can be accessed via the Investors section of EyePoint's official website.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is a clinical-stage biopharmaceutical enterprise dedicated to transforming the lives of patients suffering from severe retinal diseases. The company's leading product candidate, DURAVYU™, represents a significant advancement in the treatment of VEGF-mediated retinal conditions. Utilizing next-generation bioerodible Durasert E™ technology, DURAVYU is designed to sustain treatment delivery and improve patient outcomes.

Currently, DURAVYU is the subject of two Phase 3 pivotal trials aimed at treating wet age-related macular degeneration (wet AMD), with topline results expected in 2026. It also recently completed a successful Phase 2 trial for diabetic macular edema (DME), initiating planning for its Phase 3 trials.

Innovation and Community Commitment

EyePoint is devoted to engaging with the retina community to enhance the quality of life for patients. With four approved medications over three decades, the company proudly reflects on its history of treating tens of thousands of eyes through its innovative approaches.

Location and Licensing Information

Headquartered in Watertown, Massachusetts, EyePoint houses a commercial manufacturing facility in nearby Northbridge. Importantly, vorolanib has been exclusively licensed to EyePoint by Equinox Sciences for localized treatment of ophthalmic diseases, expanding its reach beyond certain territories in Asia.

DURAVYU has also received conditional FDA acceptance as the proprietary name for EYP-1901. While it is known that DURAVYU is still under investigation and yet to receive FDA approval, the timeline for potential approval remains uncertain.

Contact Information

Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Email: tanner.kaufman@fticonsulting.com / jenni.lu@fticonsulting.com

Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
Email: aphillips@greenroompr.com

Frequently Asked Questions

What is EyePoint Pharmaceuticals focused on?

EyePoint Pharmaceuticals is dedicated to developing innovative therapeutic solutions for serious retinal diseases.

What notable conferences is EyePoint participating in?

EyePoint will participate in Citi's BioPharma Conference, the Cantor Global Healthcare Conference, and the Morgan Stanley Annual Healthcare Conference.

What is DURAVYU?

DURAVYU is an investigational treatment for retinal diseases, designed for sustained delivery using advanced technology.

Where is EyePoint Pharmaceuticals located?

EyePoint is headquartered in Watertown, Massachusetts, with a manufacturing facility in Northbridge.

Who should I contact for more information?

For investor inquiries, contact Tanner Kaufman or Jenni Lu at FTI Consulting; for media inquiries, reach out to Amy Phillips at Green Room Communications.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Aging at Home: The Real Costs and Obstacles Ahead

Updated Category News Views 9

Facing the Realities of Aging In Place Alright, let's talk straight. Everyone dreams of staying home in their twilight years, kicking back in their favorite chair with family nearby. But the harsh truth? That comfort comes with a price tag. According to Northwestern Mutual's 2026 Planning & Progress Study, up to 83% of Boomers+ and most other generations fancy the idea of...

Continue Reading
Indiana American Water's PFAS Credits Total $25.5M

Updated Category News Views 7

Indiana American Water Dishes Out Big Buck Refunds Swing by Indiana American Water's latest move, and what do you see? A whopping $25.5 million in PFAS settlement credits being doled out to customers. That's right, this ain't your everyday water utility story—there's real money on the line here. Over four rounds of bill credits since November 2025, customers have seen...

Continue Reading
#L.A. Rising Podcast: From Fires to International Fame

Updated Category News Views 14

From Ashes to Airwaves Gritty stories of survival often cut deeper than any wonky industry analysis or corporate earnings report. When you've been through the wringer and come out the other side, that experience sticks with you—and for Kim S. Marshall, it ignited something personal yet universal with the #L.A. Rising podcast. Emerging from the 2025 L.A. fires, this...

Continue Reading
Metropolitan Dermatology's Strategic Expansion into Barnegat

Updated Category News Views 14

Diving into Barnegat's Dermatology Landscape Metropolitan Dermatology has taken a strategic step by opening a new location right in the heart of Barnegat, New Jersey. Talk about a win-win for the folks in Ocean County. This isn't just another clinic opening up shop; it's about bringing comprehensive medical and surgical dermatologic care straight to the people who need...

Continue Reading
Christmas Injury Lawyers Unveils SC Knowledge Center

Updated Category News Views 6

In the world of legal labyrinths, sometimes you just need a guiding light, especially following a car accident. That's where the freshly launched South Carolina Car Accident Law Knowledge Center steps in. It’s no magic wand, but Christmas Injury Lawyers are certainly trying to cut the chaos. This online hub covers more ground than a small library, boasting 40 guides...

Continue Reading
Palm Beach Royals Boost Pickleball's Popularity Surge

Updated Category News Views 21

A New Era for Pickleball in Palm Beach It might be time to re-evaluate pickleball if you weren't paying attention before. The Palm Beach Royals have wrapped up their first Major League Pickleball season with a bang, marking a pivotal year for the sport. This underdog tale of graft and grit is carving out a new chapter in the world of sport. Record-Breaking Season for MLP...

Continue Reading
Hilarity and Hassles in NYC Co-op Life Exposed in New Book

Updated Category News Views 16

Co-op Living: Not All It's Cracked Up to Be Let me tell you something, buying a co-op in New York City isn't just signing on the dotted line and moving in. Nope, it's a whole damn production. Jeff Namian's book, Thin Walls/Thick Ears, lays it all out with a mix of humor and hard truths, painting a stark picture of NYC co-op living. He's not just telling his own story of...

Continue Reading
OMLYCLO Shakes Up U.S. Biologic Market as Key Player

Updated Category News Views 14

Ah, the pharmaceutical game is shifting again, and this time Celltrion USA's putting their chips down with OMLYCLO, the shiny new omalizumab biosimilar. Here we see a product that's not just approved but interchangeable with XOLAIR, making it a front-runner in the allergic and inflammatory conditions battleground. If you're a patient or a provider navigating these murky...

Continue Reading
TRIMAX Poised to Meet AI-Driven Power Challenges

Updated Category News Views 11

TRIMAX's Bold Move into AI-Powered Infrastructure It feels like we're standing on the cusp of a seismic shift, folks. Artificial intelligence isn't just another buzzword anymore—it's a juggernaut reshaping our digital world. TRIMAX Power Systems is gearing up to ride this wave, with its eyes set on capturing a chunk of the booming demand for fast-deployable power...

Continue Reading
Hiromi Asai's Akatsuki Shines at Paris Fashion Week

Updated Category News Views 11

An Ode to Tradition Amid Modern Menswear From the bustling avenues of New York to the storied streets of Paris, Hiromi Asai is showcasing something that strikes a chord deep in the fashion industry's soul. Her Spring/Summer 2027 collection, "Akatsuki — Before the Dawn," takes its rare blend of age-old Japanese textile craftsmanship across the pond to the City of Light....

Continue Reading

Top 5 Most Recently Viewed Articles

Analysts Revise Projections for Keysight Following Q4 Earnings

Updated Category News Views 157

Keysight Technologies Reports Optimistic Q4 Results Keysight Technologies, Inc. (NASDAQ: KEYS) has recently made headlines by delivering stellar fourth-quarter earnings results that exceeded market expectations. The company reported quarterly earnings of $1.91 per share, surpassing the consensus estimate of $1.83. In addition, Keysight's quarterly revenue reached $1.42...

Continue Reading
Liberty Defense's HEXWAVE™ Enhances Safety at JFK Airport

Updated Category News Views 158

Liberty Defense Set to Revolutionize Security at JFK Liberty Defense Holdings Ltd., a forefront leader in technology for detecting concealed weapons and threats, is thrilled to announce that its innovative HEXWAVE™ systems will be incorporated into the aviation worker screening checkpoints at the New Terminal One at JFK International Airport. This all-international...

Continue Reading
Living Water International Welcomes New Leadership Team

Updated Category News Views 140

Living Water International Welcomes New Leadership Team Living Water International, a prominent Christian nonprofit renowned for its commitment to sustainable water, sanitation, and hygiene (WASH) solutions, has made significant strides in its leadership structure. The organization proudly announces Dr. Jonathan Wiles as its new Chief Executive Officer, while Dr. Mike...

Continue Reading
Stellantis and IVECO to Launch Electric Vans Across Europe

Updated Category News Views 207

Stellantis and IVECO's Exciting Collaboration The commercial vehicles division of Stellantis N.V., known as Stellantis Pro One, has partnered with IVECO, a respected Italian manufacturer, to bring two fully electric light commercial vehicles (LCVs) to the European market. This strategic partnership marks a significant step toward enhancing the electric vehicle landscape...

Continue Reading
Prime Medicine Previews Innovations in Genetic Therapy Research

Updated Category News Views 36

Prime Medicine Showcases Groundbreaking Preclinical Research Prime Medicine, Inc. (Nasdaq: PRME), a cutting-edge biotechnology company, is making waves with promising new advancements in genetic therapies. They are gearing up to present their innovative research, focused particularly on Wilson's Disease, at two pivotal scientific conferences. This cutting-edge research...

Continue Reading